Association of Intravenous Drug Use and Length of Stay Following Infective Endocarditis

J Surg Res. 2023 Feb:282:239-245. doi: 10.1016/j.jss.2022.10.004. Epub 2022 Nov 1.

Abstract

Introduction: Intravenous drug use (IVDU) and associated infective endocarditis (IE) has been on the rise in the US since the beginning of the opioid epidemic. IVDU-IE has high morbidity and mortality, and treatment can be lengthy. We aim to quantify the association between IVDU and length of stay (LOS) in IE patients.

Methods: The National Inpatient Sample database was used to identify IE patients, which was then stratified into IVDU-IE and non-IVDU-IE groups. Weighted values of hospitalizations were used to generate national estimates. Multivariable linear and logistic regression analyses were applied to estimate the effects of IVDU on LOS.

Results: We identified 1,114,257 adult IE patients, among which 123,409 (11.1%) were IVDU-IE. Compared to non-IVDU-IE patients, IVDU-IE patients were younger, had fewer comorbidities, and had an overall longer LOS (median [interquartile range]: 10 [5-20] versus 7 [4-13] d, P < 0.001), with a greater percentage of patients with a LOS longer than 30 d (13.7% versus 5.7%, P < 0.001). After adjusting for multiple demographic and clinical factors, IVDU was independently associated with a 1.25-d increase in LOS (beta-coefficient = 1.25, 95% confidence interval [CI]: 0.95-1.54, P < 0.001) and 35% higher odds of being hospitalized for more than 30 d (odds ratio = 1.35, 95% CI: 1.27-1.44, P < 0.001).

Conclusions: Among IE patients, being IVDU has associated with a longer LOS and a higher risk of prolonged hospital stay. Steps toward the prevention of IE in the IVDU population should be taken to avoid an undue burden on the healthcare system.

Keywords: Infective endocarditis; Intravenous drug use; Length of stay; Outcomes.

MeSH terms

  • Adult
  • Endocarditis* / drug therapy
  • Endocarditis* / epidemiology
  • Endocarditis* / etiology
  • Hospitalization
  • Humans
  • Length of Stay
  • Retrospective Studies
  • Substance Abuse, Intravenous* / complications
  • Substance Abuse, Intravenous* / epidemiology